Literature DB >> 15810645

Circulating cell-derived microparticles in Crohn's disease.

Patrick Chamouard1, Dominique Desprez, Bénédicte Hugel, Corinne Kunzelmann, Carole Gidon-Jeangirard, Michel Lessard, René Baumann, Jean-Marie Freyssinet, Lélia Grunebaum.   

Abstract

Procoagulant membrane microparticles can be released from activated or apoptotic cells in response to various environmental stimuli. The aim of this study was to investigate the presence of microparticles in Crohn's disease and to assess their variations after infliximab therapy. We compared the levels of circulating microparticles in 38 patients with Crohn's disease, 16 patients with ulcerative colitis, 7 patients with infectious colitis, and 17 control subjects. The evolution of microparticle levels was assessed after infliximab therapy in 13 patients with Crohn's disease. Circulating microparticle levels were elevated in patients with Crohn's disease (9.31+/-0.66 nmol/L phosphatidylserine equivalent [PS Eq]) or infectious colitis (10.71+/-0.92 nmol/L PS Eq) compared to patients with ulcerative colitis (5.75+/-0.59 nmol/L PS Eq) and control subjects (4.06+/-0.37 nmol/L PS Eq) (P = 0.001). Infliximab induced a significant diminution of the amounts of circulating microparticles, from 10.33+/-1.20 to 6.45+/-0.90 nmol/L PS Eq (P = 0.002). Generation of circulating microparticles occurs in Crohn's disease; infliximab induces significant diminution. Release of microparticles could be linked to the type of inflammatory response underlying Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810645     DOI: 10.1007/s10620-005-2477-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease.

Authors:  J Agnholt; K Kaltoft
Journal:  Cytokine       Date:  2001-08-21       Impact factor: 3.861

3.  Annexin V inhibits protein kinase C activity via a mechanism of phospholipid sequestration.

Authors:  T Dubois; J P Mira; D Feliers; E Solito; F Russo-Marie; J P Oudinet
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

4.  Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour?

Authors:  E Louis; M Peeters; D Franchimont; L Seidel; F Fontaine; G Demolin; F Croes; P Dupont; L Davin; S Omri; P Rutgeerts; J Belaiche
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

5.  Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes.

Authors:  C Pigault; A Follenius-Wund; M Schmutz; J M Freyssinet; A Brisson
Journal:  J Mol Biol       Date:  1994-02-11       Impact factor: 5.469

6.  Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells.

Authors:  O Fourcade; M F Simon; C Viodé; N Rugani; F Leballe; A Ragab; B Fournié; L Sarda; H Chap
Journal:  Cell       Date:  1995-03-24       Impact factor: 41.582

7.  Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A.

Authors:  Ingrid Hrachovinová; Beatrice Cambien; Ali Hafezi-Moghadam; János Kappelmayer; Raymond T Camphausen; Angela Widom; Lijun Xia; Haig H Kazazian; Robert G Schaub; Rodger P McEver; Denisa D Wagner
Journal:  Nat Med       Date:  2003-07-13       Impact factor: 53.440

8.  Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder.

Authors:  F Toti; N Satta; E Fressinaud; D Meyer; J M Freyssinet
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

9.  Hemostatic alterations in inflammatory bowel disease: response to therapy.

Authors:  A M Lake; J Q Stauffer; M J Stuart
Journal:  Am J Dig Dis       Date:  1978-10

10.  Raised plasma concentrations of platelet factor 4 (PF4) in Crohn's disease.

Authors:  M Simi; S Leardi; M T Tebano; M Castelli; F M Costantini; V Speranza
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

View more
  13 in total

Review 1.  Multipotent role of platelets in inflammatory bowel diseases: a clinical approach.

Authors:  Evangelos Voudoukis; Konstantinos Karmiris; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

2.  How do megakaryocytic microparticles target and deliver cargo to alter the fate of hematopoietic stem cells?

Authors:  Jinlin Jiang; Chen-Yuan Kao; Eleftherios T Papoutsakis
Journal:  J Control Release       Date:  2016-12-24       Impact factor: 9.776

Review 3.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

4.  Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.

Authors:  Grace M Thomas; Laurence Panicot-Dubois; Romaric Lacroix; Françoise Dignat-George; Dominique Lombardo; Christophe Dubois
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

5.  Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome.

Authors:  Abdelali Agouni; Anne Hélène Lagrue-Lak-Hal; Pierre Henri Ducluzeau; Hadj Ahmed Mostefai; Catherine Draunet-Busson; Georges Leftheriotis; Christophe Heymes; Maria Carmen Martinez; Ramaroson Andriantsitohaina
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

6.  Factor v leiden and inflammation.

Authors:  Silvia Perez-Pujol; Omer Aras; Gines Escolar
Journal:  Thrombosis       Date:  2012-05-14

7.  Circulating microparticles from Crohn's disease patients cause endothelial and vascular dysfunctions.

Authors:  Daniela Leonetti; Jean-Marie Reimund; Angela Tesse; Stéphanie Viennot; Maria Carmen Martinez; Anne-Laure Bretagne; Ramaroson Andriantsitohaina
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

Review 8.  Update on current applications of proteomic in the study of inflammatory bowel disease.

Authors:  Giulia Roda; Alessandra Caponi; Alessandro Sartini; Monica Cevenini; Carolina Colliva; Aldo Roda
Journal:  Ann Gastroenterol       Date:  2012

Review 9.  Microparticles: a new perspective in central nervous system disorders.

Authors:  Stephanie M Schindler; Jonathan P Little; Andis Klegeris
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

10.  Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity.

Authors:  Jérémie Sellam; Valérie Proulle; Astrid Jüngel; Marc Ittah; Corinne Miceli Richard; Jacques-Eric Gottenberg; Florence Toti; Joelle Benessiano; Steffen Gay; Jean-Marie Freyssinet; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-10-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.